Pretreatment anti-mullerian hormone to predict for resumption of mense in one year after chemotherapy in premenopausal hormone-receptor positive early breast cancer.

e12032Background: Postchemotherapy ovarian function is very important in relation to adjuvant endocrine therapy decisions of hormone receptor-positive (HR+) early breast cancer (eBC). Although menses status is commonly used to measure ovarian function after chemotherapy, its retrospective pattern limited the prospective application in endocrine therapy plan making. Anti-mullerian hormone (AMH) is now the gold standard to measure ovarian reserve function in reproductive medicine. The purpose of this study was to evaluate the association of prechemotherapy AMH, follicle-stimulating hormone (FSH) and estrogen (E) with resumption of menses in one year after chemotherapy. Methods: This is a retrospective study. From August 2013 to December 2014, a total of 120 premenopausal patients younger than 50 years old with HR+ eBC were included in this study. We tested the relationship between prechemotherapy AMH, FSH and E with one year menses status. Results: After a median follow up of 446 days (range, 182-790 days) ...